journal article·2026-07-21Open access

Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

Jonas Engelhardt, Nico Kirsch, Aileen Kerfin, Lars P. Lunding, Dominic Ferber, Hannes Buthmann, Ilka Schreier, Carlotta Bosio, Ann‐Kathrin Dobbelstein, Anna Klawonn, Rebecca C. Coll, Lena Bauernhofer, Sandro Keller, Matthias Geyer, Michael Wegmann, Andra B. Schromm, Günther Weindl

Abstract

ABSTRACT The NLRP3 inflammasome is a multi‐protein complex that plays a crucial role in inflammatory processes mediated by the innate immune system. Dysregulated NLRP3 activation has been implicated in age‐related inflammatory diseases, making it a promising therapeutic target. Here, we report that the synthetic membrane‐active antimicrobial peptide Pep19‐2.5 directly inhibits NLRP3 inflammasome activation. Through cellular, biophysical, and biochemical analyses, we find that Pep19‐2.5 suppresses NLRP3 inflammasome signaling downstream of NLRP3 activation. Pep19‐2.5 interacts with macrophage membranes, supporting a membrane‐targeting mechanism for its anti‐inflammatory effects. Mechanistically, Pep19‐2.5 binds to phosphatidylinositol (PI)‐containing lipid membranes and dispersed trans‐Golgi network (dTGN) structures, which could potentially affect NLRP3 recruitment to the dTGN. We demonstrate a strong and NLRP3‐dependent induction of IL‐1β secretion from human macrophages by house dust mite (HDM) extract, which can be inhibited by Pep19‐2.5. In line with these findings, therapeutic application of Pep19‐2.5 via the nasal aerosol route reduces IL‐1β levels, eosinophil infiltration in bronchoalveolar lavage and significantly improved lung function in an in vivo HDM‐mouse model of allergic airway inflammation. Our findings highlight the therapeutic potential of targeting NLRP3 activation by the small membrane‐active peptide Pep19‐2.5 for the treatment of NLRP3‐driven inflammatory diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Cellular transport and secretion · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutical Institute, Section Pharmacology and Toxicology University of Bonn Bonn Germany

Division of Immunobiophysics, Priority Area Infections, Research Center Borstel, Leibniz Lung Center Member of Leibniz Health Technologies Borstel Germany

Division of Lung Immunology, Priority Area Chronic Lung Diseases, Research Center Borstel Leibniz Lung Center Borstel Germany

Airway Research North (ARCN) German Center for Lung Research (DZL) Borstel Germany

Institute of Structural Biology University of Bonn Bonn Germany

Wellcome‐Wolfson Institute for Experimental Medicine Queen's University Belfast Belfast UK

Biophysics, Institute of Molecular Biosciences (IMB), NAWI Graz University of Graz Graz Austria

Field of Excellence Biohealth University of Graz Graz Austria

BioTechMed‐Graz Graz Austria

Kiel Nano, Surface and Interface Science KiNSIS Kiel University Kiel Germany

References (71)

Show source-provided references
1. 10.1038/s41392‐021‐00687‐010.1038/s41392‐021‐00687‐0 ↗
2. 10.1016/j.cell.2020.02.04110.1016/j.cell.2020.02.041 ↗
3. 10.1016/j.cell.2024.03.03610.1016/j.cell.2024.03.036 ↗
4. 10.1146/annurev.immunol.021908.13261210.1146/annurev.immunol.021908.132612 ↗
5. 10.1038/nri.2016.5810.1038/nri.2016.58 ↗
6. 10.1038/s41577‐019‐0165‐010.1038/s41577‐019‐0165‐0 ↗
7. 10.1038/s41423‐021‐00670‐310.1038/s41423‐021‐00670‐3 ↗
8. 10.1038/s41573‐023‐00822‐210.1038/s41573‐023‐00822‐2 ↗
9. 10.1038/s41586‐018‐0761‐310.1038/s41586‐018‐0761‐3 ↗
10. 10.1126/scisignal.abm713410.1126/scisignal.abm7134 ↗
11. 10.1016/j.immuni.2022.10.02110.1016/j.immuni.2022.10.021 ↗
12. 10.1038/s41590‐022‐01355‐310.1038/s41590‐022‐01355‐3 ↗
13. 10.1016/j.celrep.2024.11407010.1016/j.celrep.2024.114070 ↗
14. 10.7554/eLife.94302.310.7554/eLife.94302.3 ↗
15. 10.1016/j.celrep.2024.11460910.1016/j.celrep.2024.114609 ↗
16. 10.1016/j.molcel.2024.08.00110.1016/j.molcel.2024.08.001 ↗
17. 10.1126/science.118400310.1126/science.1184003 ↗
18. 10.1038/s41590‐023‐01526‐w10.1038/s41590‐023‐01526‐w ↗
19. 10.1038/s41590‐025‐02230‐710.1038/s41590‐025‐02230‐7 ↗
20. 10.1016/j.tips.2022.04.00310.1016/j.tips.2022.04.003 ↗
21. 10.1038/s41573‐019‐0058‐810.1038/s41573‐019‐0058‐8 ↗
22. 10.1021/acsinfecdis.3c0067310.1021/acsinfecdis.3c00673 ↗
23. 10.1016/j.tips.2019.01.00110.1016/j.tips.2019.01.001 ↗
24. 10.1080/14787210.2021.183484710.1080/14787210.2021.1834847 ↗
25. 10.3389/fphar.2018.0028110.3389/fphar.2018.00281 ↗
26. 10.1073/pnas.210172111810.1073/pnas.2101721118 ↗
27. 10.1038/s41579‐025‐01200‐y10.1038/s41579‐025‐01200‐y ↗
28. 10.1038/s41467‐025‐60277‐410.1038/s41467‐025‐60277‐4 ↗
29. 10.1038/s41423‐022‐00922‐w10.1038/s41423‐022‐00922‐w ↗
30. 10.3389/fimmu.2018.0170410.3389/fimmu.2018.01704 ↗
31. 10.1111/bph.1442510.1111/bph.14425 ↗
32. 10.1021/acsptsci.4c0049610.1021/acsptsci.4c00496 ↗
33. 10.1038/srep3157710.1038/srep31577 ↗
34. 10.1016/j.bcp.2017.05.01510.1016/j.bcp.2017.05.015 ↗
35. 10.1016/j.immuni.2019.05.02010.1016/j.immuni.2019.05.020 ↗
36. 10.3390/ijms2203146510.3390/ijms22031465 ↗
37. 10.1016/j.immuni.2013.05.01610.1016/j.immuni.2013.05.016 ↗
38. 10.1021/ja00211a01210.1021/ja00211a012 ↗
39. 10.4049/jimmunol.140265810.4049/jimmunol.1402658 ↗
40. 10.1016/j.immuni.2024.04.01510.1016/j.immuni.2024.04.015 ↗
41. 10.1084/jem.2019031410.1084/jem.20190314 ↗
42. 10.1021/bi00630a00210.1021/bi00630a002 ↗
43. 10.1126/sciadv.abn758310.1126/sciadv.abn7583 ↗
44. 10.1101/2025.03.30.64620510.1101/2025.03.30.646205 ↗
45. 10.1038/s41586‐022‐04467‐w10.1038/s41586‐022‐04467‐w ↗
46. 10.1083/jcb.20231009510.1083/jcb.202310095 ↗
47. 10.1038/s41586‐024‐07487‐w10.1038/s41586‐024‐07487‐w ↗
48. 10.1016/S0140‐6736(20)30925‐910.1016/S0140‐6736(20)30925‐9 ↗
49. 10.1016/j.jaip.2018.01.02510.1016/j.jaip.2018.01.025 ↗
50. 10.1183/16000617.0176‐202110.1183/16000617.0176‐2021 ↗
51. 10.1016/0091‐6749(89)90006‐710.1016/0091‐6749(89)90006‐7 ↗
52. 10.1111/all.1507210.1111/all.15072 ↗
53. 10.1111/all.1516410.1111/all.15164 ↗
54. 10.1128/AAC.02066‐1210.1128/AAC.02066‐12 ↗
55. 10.1016/j.it.2025.10.00810.1016/j.it.2025.10.008 ↗
56. 10.1038/s41590‐025‐02280‐x10.1038/s41590‐025‐02280‐x ↗
57. 10.1038/s41392‐024‐01801‐810.1038/s41392‐024‐01801‐8 ↗
58. 10.1101/2023.07.07.54807510.1101/2023.07.07.548075 ↗
59. 10.1016/j.immuni.2011.03.01510.1016/j.immuni.2011.03.015 ↗
60. 10.1111/febs.1480510.1111/febs.14805 ↗
61. 10.1016/j.ejmech.2023.11538610.1016/j.ejmech.2023.115386 ↗
62. 10.1084/jem.2024240310.1084/jem.20242403 ↗
63. 10.1080/15548627.2019.168672810.1080/15548627.2019.1686728 ↗
64. 10.1016/j.bcp.2020.11386410.1016/j.bcp.2020.113864 ↗
65. 10.1016/j.bcp.2023.11569310.1016/j.bcp.2023.115693 ↗
66. 10.4049/jimmunol.140111010.4049/jimmunol.1401110 ↗
67. 10.1016/j.xpro.2022.10184810.1016/j.xpro.2022.101848 ↗
68. 10.1371/journal.pgen.100961910.1371/journal.pgen.1009619 ↗
69. 10.1111/j.1365‐2818.1990.tb03036.x10.1111/j.1365‐2818.1990.tb03036.x ↗
70. 10.1007/s00428005016010.1007/s004280050160 ↗
71. 10.4049/jimmunol.140252910.4049/jimmunol.1402529 ↗